Dozens seek help at rail station mental health hub
"The Hub" was launched by West Midlands Railway (WMR) and charity Rethink Mental Illness at Wolverhampton Station, in May.
It is providing people with support and guidance, as well as offering a space for local organisations to run pop-ups and events.
"The Hub has been extremely successful in its first four weeks of opening," said Samantha Passmore, Wolverhampton customer experience manager for WMR.
"We have had dozens of people enquiring about advice and additional support, and more and more charities are requesting to use the facility, which was our vision from day one.
"We look forward to seeing the Hub go from strength to strength over the coming months."
Organisations already using the site have included employment support service Thrive into Work, and Children in CueSports - which provides pathways into sport.
"In just a few weeks, we've seen how much of a difference it can make to have an accessible space where people feel able to reach out for help," said Kirsten Rose, service manager at Rethink Mental Illness - which maintains and staffs the site.
"It's a great example of what's possible when organisations come together to put mental health at the heart of local communities."
The initiative is backed by Black Country Healthcare NHS Foundation – the lead provider of mental health and learning disability services in the region.
Its chief nurse Carolyn Green, said they had seen increased interest in their services since the hub opened.
"This includes our 24/7 mental health helpline, our sanctuary hubs, the Black Country Recovery College, and free suicide prevention training for families and carers," she said.
"Having somewhere that signposts to these services in a visible, public location really matters and we believe it is, and will continue to be, life-saving."
Follow BBC Wolverhampton & Black Country on BBC Sounds, Facebook, X and Instagram.
Hub aims to help rail passengers in crisis
Former radio station studio up for auction
West Midlands Railway
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
How does Mayor Kerry Thomson plan to end homelessness in Bloomington? By keeping it local.
Street homelessness in Bloomington is far reaching and out of control, a situation mayor Kerry Thomson intends to rein in. During a July 29 press conference focused on the city's housing and homelessness response, Thomson said her administration will take substantive steps to end homelessness. She made clear that the city's efforts to provide mental health and substance use disorder treatment, life skills and housing will be provided to people from within the 6-county federal region that includes Bloomington. Bloomington-based non-profit Heading Home is tasked with helping decrease homelessness in the six counties but has extended its scope to assist anyone without a place to live who comes to Bloomington. Thomson, who serves on Heading Home's board of directors, disagrees with the agency's policy to offer local services to anyone experiencing homelessness no matter where they are from. By removing residency requirements, Heading Home's housing plan hinders the city's ability to provide comprehensive help to homeless people from Monroe and the other five other counties federal funds provide are designate for, Thomson said. Since there aren't enough resources to help everyone when they are spread too thin, Thomson said, the ability to fully help people fades. She said the homeless situation in Bloomington exemplifies 'what happens when we do not draw boundaries around who we can and cannot serve.' 'Cease sending people to Bloomington' She suggested other communities step up and help their own instead of driving them to a distant place away from the familiarity of home and a support network of family and friends. The mayor said Bloomington's social service network has been overwhelmed by the challenges — from crime to health issues — of having so many unhoused people living on the streets and in wooded encampments. No longer, the mayor said, will the city provide services to just anyone who lands homeless in Bloomington — they must have ties to Monroe, Morgan, Owen, Greene, Lawrence or Martin counties. Thomson asked other cities 'to cease sending people to Bloomington if they are not from here.' The recently hired homeless services coordinator has been calling municipalities to spread the message. Thomson said police and agencies that assist unhoused people bring them to Bloomington and drop them off so they can access the city's services. 'We continue to meet people on the streets who are not from our region,' Thomson said, reiterating that the city cannot provide care and housing for everyone who shows up. 'Dropping them off here, they end up in encampments and they lose any ties at all they have to family and friends who may be able to help them,' she said. Long-term homelessness often results. 'Our community's mission is to get our heads above water, to truly end the cycle of homelessness for the people in our HUD district.' She said outsiders sometimes end up in Bloomington for addiction treatment or get admitted to IU Health-Bloomington Hospital with medical problems, then are released with no resources and nowhere to go. Others, many just out of state prisons, find temporary shelter at Wheeler Mission and then stay in Bloomington, often living on the streets. More: Lilly grant How the community plans to spend a $7.4 million grant to combat homelessness Bloomington, Thomson said, cannot manage the influx. The city and other agencies have what are called 'reunification funds' earmarked for transporting transient people back to their home counties to live. So with a renewed focus using Lilly grant funds for intervention workers and case managers to re-direct the lives of local homeless people, the city moves forward. Spokeswoman Desiree DeMolina summed up the city's stance. "Our community cannot serve as the destination for every person in crisis across the state," she said in an email response to questions. "When resources are stretched too thin, no one gets the support they need. Caring means knowing the limit." Police crack down on homeless drug dealing Part of the initiative involves police intervention to stem drug selling that's rampant in the homeless community. Dealing-related arrests at Seminary Park on July 25 and more at Crawford Apartments the day of the mayor's press conference reflect the ongoing effort to address the out-of-hand situation. 'We can't arrest our way out of the homeless problem,' Thomson said, adding that law enforcement is necessary. 'We are taking a stand against the dealers in our community who are taking advantage of people with substance use disorder and causing extreme challenges and more difficult lives for those who are the most vulnerable.' She challenged the notion that homelessness is an intractable problem here to stay. 'If there's any community in Indiana that can end homelessness,' Thomson said, 'it's Bloomington, Indiana.' Contact H-T reporter Laura Lane at llane@ or 812-318-5967. This article originally appeared on The Herald-Times: Bloomington mayor offers insights to ending homelessness in city Solve the daily Crossword
Associated Press
38 minutes ago
- Associated Press
Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides
SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the 'Company'), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced that its drug candidate NV-387 is the weapon necessary for combatting growing cases of measles worldwide, especially in the industrialized world including, USA, Canada, UK, and European Union. NV-387 is possibly the only drug candidate that has been shown to be effective and safe in animal model studies of Measles virus in humanized h-CD150+ knock-in mice, as reported previously by NanoViricides. NV-387 has completed a Phase I clinical trial with no reported adverse events, indicating excellent safety and tolerability in humans. The development of NV-387 as a treatment for Measles can be accelerated under the US FDA programs. Measles is considered a rare orphan disease in the USA. As such, NV-387 for the treatment of Measles would qualify for an Orphan Drug Designation. Orphan drug designation qualifies sponsors for incentives including tax credits for qualified clinical trials, exemption from user fees, and potential seven years of market exclusivity after approval[1]. The Company also plans to explore a 'Fast Track' designation for the NV-387 Measles indication. If granted, a drug approval can occur on the basis of a successful Phase II clinical trial without requiring a Phase III clinical trial, which significantly reduces the timeline to approval. Measles has become an important disease of concern globally in the recent years for several reasons. Most importantly, Measles disease can wipe out the previously learned immunity of the patient against many infections, including from prior infections, and non-live virus vaccines, making the population vulnerable to viruses that were encountered previously. This is because Measles virus attacks the CD150-bearing immune cells that are responsible for memorizing the prior infections and mounting defenses against them later. Measles is possibly the most communicable diseases, spreading through aerosol, that is known to humans. In patients, it produces severe morbidity with skin rash, pain, fatigue, and other syndromes. Rarely it can cause a brain disease. Measles mostly affects children. There were a total of 1,319 confirmed measles cases reported in the USA as of July 22, breaking the most recent record of 1,274 cases in 2019. Hospitalization rates for measles in the USA are about 13%, and fatalities are rare, although in 2025 there were three deaths to date. Canada is having a much worse Measles season than the USA, with more than 3,800 cases[2] to date in 2025. A Measles holiday warning has been issued in the UK this year[3]. England itself had more than 3,000 cases of Measles in 2024. In the European Region, 127,350 measles cases were reported for 2024, double the number of cases reported for 2023 and the highest number since 1997, according to an analysis by WHO and the United Nations Children's Fund (UNICEF)[4] . Worldwide, Measles cases continue to occur every year. Globally, there have been about 108,000 confirmed measles cases in 2025 to date, while in 2024 there were about 360,000 confirmed cases, according to the WHO[5]. A sustained measles vaccination rate of at least 95% is estimated to be required to maintain community immunity ('herd immunity'). Such a high rate is becoming increasingly difficult to achieve even in developed countries where access to vaccination is not an issue. While growing vaccine hesitancy is considered an important reason for the fall in Measles vaccination rates, two other factors are of importance as well: (i) The overall population in the industrialized world, as well as in developing world, has increased frequency of immune dysfunction, obesity, and diabetes. The people with immune dysfunction or immune compromise are less likely to benefit from almost any standard vaccination as compared to healthy people and are likely to result in breakthrough infections. (ii) Additionally, the current vaccine for Measles is a live attenuated vaccine of the 1968 era, and the virus has evolved well past that, although so far the Measles virus strains continue to be susceptible to antibodies produced from the standard vaccine; this can change with continuing circulation of the virus in vaccinated persons and can result in a virus that can substantially defeat the vaccine[6]. Further, vaccine hesitancy itself is not irrational because the standard Measles vaccine is a live attenuated vaccine to be given to infants at early age; it is a virus infection that continues to remain in the subject, which is why it provides lifelong immunity. Measles infection itself also provides lifelong immunity that includes the current strains of the virus. Thus, the Company projects continuing Measles cases worldwide, that require a drug to control the disease in the patient and its spread to others. We believe NV-387 fills this important medical need. There is no approved drug for treatment of Measles at present. ABOUT NANOVIRICIDES NanoViricides, Inc. (the 'Company') ( ) is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading 'Risk Factors' and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. The phrases 'safety', 'effectiveness' and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA. FDA refers to US Food and Drug Administration. IND application refers to 'Investigational New Drug' application. cGMP refers to current Good Manufacturing Practices. CMC refers to 'Chemistry, Manufacture, and Controls'. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for 'Active Pharmaceutical Ingredient'. WHO is the World Health Organization. R&D refers to Research and Development. Contact: NanoViricides, Inc. [email protected] Public Relations Contact: [email protected] press release
Yahoo
an hour ago
- Yahoo
BrainsWay to Report Second Quarter 2025 Financial Results on August 13, 2025
BURLINGTON, Mass. and JERUSALEM, July 30, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ('BrainsWay' or the 'Company'), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its second quarter 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Wednesday, August 13, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date: Wednesday, August 13, 2025 Time: 8:30 AM Eastern Time United States: 1-877-300-8521 International: 1-412-317-6026 Israel: 1-80-921-2373 Conference ID: 10201287 Webcast: Link The conference call will be broadcast live and will be available for replay for 30 days on the Company's website, Please access the Company's website at least 10 minutes ahead of the conference call to register. About BrainsWayBrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit Contacts: BrainsWay:Ido MaromChief Financial Investors:Brian RitchieLifeSci Advisorsbritchie@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
